Alnylam Grants MWG Biotech License to Fundamental RNAi Patents for Applications in the Research Products Market
"This agreement with MWG, an international genomic solution provider, continues to highlight the value of the Alnylam-owned Kreutzer-Limmer patent family as a critical component of fundamental intellectual property in the field of RNAi," said Vincent Miles, Ph.D., Senior Vice President, Business Development of Alnylam Pharmaceuticals. "By leveraging our portfolio of leading IP, we are creating value today and for the future by amassing an increasing number of license agreements with leading reagent and service providers. To date, fourteen companies have taken licenses for therapeutic or research product applications, including eight research product suppliers."
"This license strengthens our siRNA offering and is part of our commitment to build a high quality presence in siRNA design and production," said Dr. Wolfgang Pieken, CEO of MWG Biotech AG.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.